

Interventional Fluoroscopy Procedures

Images have been removed
Due to copyright restrictions

Stephen Balter, Ph.D.

FAAPM, FACR, FACMP, FSIR
Professor of Clinical Radiology (Physics) (in Medicine)

AAPM - August 2013



SB1308 - AAPM - 1

© S. Balter 2013

Learning Objectives

- Effects on patient's skin, hair, eyes, and other tissues.
- The use of controls and real-time displays of radiation quantities; their relation to radiation risks.
- Adequate communication of radiation risk
 - As part of the informed consent process
 - Post-procedure

SB1308 - AAPM - 2

© S. Balter 2013

Background

- Most FGI procedures have several associated major risks.
- Procedures might require a substantial amount of radiation for their completion.
- Radiation should be regarded as a toxic agent in the same sense as contrast-media and pharmaceuticals.
- Managing all toxic agents should be a part of a continuous benefit-risk assessment.

SB1308 - AAPM - 3

© S. Balter 2013

Some non-radiation risks

- Serious allergic reaction to contrast materials (Iodine).
- Kidney injury due to the contrast material.
- Damage to the blood vessel, bruising or bleeding at the puncture site, and infection.
- Blood forms a clot around the tip of the catheter, blocking the artery and making it necessary to operate to reopen the vessel.
- Stroke if the catheter dislodges plaque from a vessel wall that blocks blood flow within the brain.
- The catheter punctures an artery, causing internal bleeding.

Adapted from Cerebral Angiography @ radiologyinfo.org Accessed May 2013

SB1308 - AAPM - 4

© S. Balter 2013

Justification and Optimization

- Operators need to know
 - Biological risks at different dose levels
 - Clinical factors that might modify risk
 - Radiation status during the procedure
- Optimization
 - Equipment construction and configuration
 - Physics QA (beyond regulatory minimum)
 - Operator's utilization of equipment features
 - Operator's clinical abilities

SB1308 - AAPM - 5

© S. Balter 2013

BIOLOGY
and
CLINICAL

SB1308 - AAPM - 6

© S. Balter 2013

Radiogenic Risk

- Hair loss (temporary or permanent)
- Injury of skin and subcutaneous tissues.
- Bone injury
- Radiogenic cataract
- Non-cancer vessel and organ damage

SB1308 – AAPM - 7 © S. Balter 2013

Radiation Effects Chart

Grade	Single Site Acute Skin Size Range (cm ²)	R ₅₀ Skin Reaction Grade*	Approximate Time of Onset of Effects			
			Proximal	Earls	Midline	Ling Term
A1	0-2	NA ¹	No observable effects expected	No observable effects expected	No observable effects expected	No observable effects expected
A2	2-5	1	Transient erythema	Erythema	Recovery from hair loss	No observable results expected
B	5-10	1-2	Transient erythema	Erythema, epilation	Recovery at higher doses, prolonged erythema, permanent partial epilation	Recovery at higher doses, dermal atrophy or induration
C	10-15	2-3	Transient erythema	Erythema, epilation, possible dry or moist desquamation, recovery from desquamation	Prolonged erythema, permanent epilation	Intergrowth ² , dermal atrophy or induration, skin likely to be weak
D	>15	3-4	Transient erythema, ulcer very high doses, edema and acute ulceration, long-term surgical intervention likely to be required	Erythema, epilation, moist desquamation	Dermal atrophy, secondary ulceration due to failure of moist desquamation to heal, surgical intervention likely to be required, at higher doses, dermal necrosis, surgical intervention likely to be required	Intergrowth ² , dermal atrophy or induration, possible late skin breakdown/ulcer, might be prevented and progress into a deeper lesion, surgical intervention likely to be required

Note: — Applicable to normal range of patient self-administration in absence of radiating or approximating physical or clinical factors. Data do not apply to the skin of the scalp, face and feet/heels and not light hair-bearing. Signs and symptoms are expected to appear earlier in skin dose increases. Proximal < 2 weeks, early, 2-4 weeks, midline, 4-12 weeks, Ling term, > 12 weeks.
 * Skin dose refers to actual skin dose (including backscatter). This quantity is not the entrance point air kerma described by ICRU and IAEA Commission (1998) or International Commission on Radiological Units (ICRU). Skin dose may be more accurate than > 50% NA = not applicable.
¹ R₅₀ = National Cancer Institute.
² refers to radiation-induced intergrowth. Intergrowth associated with area of initial moist desquamation or healing of ulceration may be present earlier.

SB1308 – AAPM - 8 © S. Balter 2013

Tissue Reactions

SB1308 – AAPM - 9 © S. Balter 2013

Radiation Therapy Injuries

Bolus Radiation Recall

SB1308 – AAPM - 10 © S. Balter 2013

Time sequence

2 months 6 months 2 years

Source: FDA/CDRH

SB1308 – AAPM - 11 © S. Balter 2013

Multiple procedures

- Biology
 - DNA repair complete in 24 hours
 - Skin cell death in approximately 30 days
 - Skin cells replaced in approximately 60 days
 - Microvasculature damage.
- “Routine” interval between stages
 - 4 to 6 weeks for different anatomy.
 - 8 to 12 weeks for same anatomy.
 - Examine patient’s skin immediately before starting a new stage.

SB1308 – AAPM - 12 © S. Balter 2013

Poor practice

2 m p 1 5 m p 1
 1 m p 2

6 m p 1 pre
 2 m p 2 op

SB1308 - AAPM - 13 © S. Balter 2013

Management of a known reaction

1 m 2 m

SB1308 - AAPM - 14 © S. Balter 2013

TECHNOLOGY

SB1308 - AAPM - 15 © S. Balter 2013

WIP - Real Time Skin Dose Mapping

SB1308 - AAPM - 16 © S. Balter 2013

Clinical Selections

Head and Neck
Chest
Heart
Low (F-I, C-I) (LDT)
Medium (F-I, C-I) (SDT)
High (F-A, C-I) (SDT)
Special Ultra Low (F-I, C-I) (XLDT)
Special High (F-A, C-I) (SDT)
Electrophysiology
Great Vessels
Abdomen
Pelvis
Extremities
Special

X-RAY AVAILABLE	CINE LOW	CINE HIGH
Fluoro LOW	Fluoro Medium	Fluoro High
STORE Fluoro	Fluoro 10 fps	CINE 15 fps

Control Panel Table Side

SB1308 - AAPM - 17 © S. Balter 2013

Dose rates - Mode

1 second of DSA
 3-6 seconds of Cine
 30-60 seconds of Fluoro

SB1308 - AAPM - 18 © S. Balter 2013

Dose rates – Fluoro Frame Rate

SB1308 – AAPM - 19 © S. Balter 2013

In-lab cumulative radiation displays

System is set for low dose rate fluoroscopy using 15 fps

Totals from the start of the procedure:

Fluoroscopy time → time (min) 10.6

Air Kerma Area Product → DAP (Gycm²) 122

Air Kerma at the reference point → AK (mGy) 1980

Provided so that the operator can track total radiation used as each procedure progresses !

SB1308 – AAPM - 20 © S. Balter 2013

Fluoroscopy Time

≈2,100 non-cardiac interventions

$$K_{air} = 0.41 + 0.037 F_{min}$$

$R^2 = 0.50$

RAD-IR I

≈1,700 coronary-artery procedures

$$K_{air} = 0.53 + 0.12 F_{min}$$

$R^2 = 0.68$

IAEA-SRS 59

SB1308 – AAPM - 21 © S. Balter 2013

Notifications (NCRP-168)

TABLE 4.7—Suggested values for first and subsequent notifications and the SRDL.

Dose Metric	First Notification	Subsequent Notifications (increments)	SRDL
$D_{skin,max}$	2 Gy	0.5 Gy	3 Gy
K_{air}	3 Gy	1 Gy	5 Gy ^a
P_{KA}	300 Gy cm ² ^b	100 Gy cm ² ^b	500 Gy cm ² ^b
Fluoroscopy time	30 min	15 min	60 min

^aSee additional discussion concerning the value 5 Gy in Section 4.3.4.2.
^bAssuming a 100 cm² field at the patient's skin. For other field sizes, the P_{KA} values should be adjusted proportionally to the actual procedural field size (e.g., for a field size of 50 cm², the SRDL value for P_{KA} would be 250 Gy cm²).

SB1308 – AAPM - 22 © S. Balter 2013

Radiation Dose Structured Report

- RDSR is a free-standing DICOM object without private fields.
- Provides shot-by-shot irradiation data.
- Initial post-procedure implementations are available on some new equipment.
- Streaming implementations coming.
- IEC standard under development to assure a consistent data set.

SB1308 – AAPM - 23 © S. Balter 2013

c 1960 – Ad in Radiology

SB1308 – AAPM - 24 © S. Balter 2013

Drilling down to the future?

SB1308 – AAPM - 25

© S. Balter 2013

Patient Communication

SB1308 - AAPM - 26

© S. Balter 2013

Informed consent considerations


- Patient's age
- Patient's health details
- Patient's size
- Nature of the planned procedure
- Other irradiation of the same area
 - Previous interventional procedures
 - Previous or planned radiation therapy

SB1308 – AAPM - 27

© S. Balter 2013

Latent Period (years)

- Leukemia
 - Min 2 – 4
 - Max 10 – 20
- Solid Cancer
 - Min 10
 - Max > 40



Conceptual cartoon

SB1308 – AAPM - 28

© S. Balter 2013

Possible informed consent topics

- A slightly elevated risk of cancer several years or decades later in life. This risk is low in comparison to the natural risk of developing cancer.
- Skin rashes occur infrequently; on very rare occasions they may result in tissue breakdown and possibly severe ulcers.
- Hair loss may occur which can be temporary or permanent.
- Cataracts are rarely induced following neurointerventional procedures.
- You or your family will be advised if we actually used substantial amounts of radiation during the case. If this happens, you will be given appropriate instructions prior to discharge.

Based on NCRP Report 168

SB1308 – AAPM - 29

© S. Balter 2013

Substantial Dose Procedures

- > 5,000 mGy – Less if clinically warranted.
- Lab provides 'hand-off' data:
- Patient receives radiation instructions
- Patient calls with possible reaction
 - Clinic visit with operator scheduled if PA can't absolutely rule out radiation.
- CUMC QA follow-up > 7,000 mGy
 - Proactive 30 – 40 days post procedure.
 - So far all patients contacted by QA with skin changes have already called us.
 - Continuing follow-up of known injuries.

SB1308 – AAPM - 30

© S. Balter 2013

Radiation discharge instructions

- Have a family member look at your back 30 days from now.
- Call us (lab's 24 hour PA emergency number) if there is a red patch the size of your hand.

Catheterization and Cardiovascular Interventions 77:246-256 (2011)

SB1308 – AAPM - 31

© S. Balter 2013

Substantial Dose (NCRP-168)

- ❖ If a substantial radiation dose level is exceeded, the patient and any caregivers should be informed, prior to discharge, about possible deterministic effects and recommended follow-up.
- ❖ Follow-up for possible deterministic effects shall remain the responsibility of the interventionalist for at least one year after an FGI procedure. Follow-up may be performed by another healthcare provider.

All relevant signs and symptoms shall be regarded as radiogenic unless an alternative diagnosis is established.

SB1308 – AAPM - 32

© S. Balter 2013

Further reading



Guidelines for Patient Radiation Dose Management

Michael S. Swisher, MD, Stephen Balter, PhD, Richard B. Jacobin, MD, Donald E. Miller, MD, Simon Yank, PhD, Gabriel Rajul, MD, E. Fritz Andra, MD, Christine F. Chin, MD, Alan M. Cohen, MD, Robert C. Orton, MD, Kathleen Green, MD, PhD, E. N. George C. Harshbarger, MD, Beth Schwartz, PhD, John D. Sauer, MD, Thierry de Fombes, MD, and John F. Costello, MD, for the NCR Safety and Health Committee and the ICRS Standards of Practice Committee

1 Nov 2008; Revised June 2010; 2011

SB1308 – AAPM - 33

© S. Balter 2013